Understanding Palbociclib: A Medication Profile

Summary or Key Points

Palbociclib, also known by the brand name Ibrance, is a prescription medication primarily used in the treatment of specific types of breast cancer. As a targeted therapy, it works by interfering with the growth of cancer cells. Key points in this article cover its usage, dosing, side effects, cost, and possible alternatives.

Names of Medication

US Brand Name: Ibrance

Generic Name: Palbociclib

The term ‘generic name’ refers to the official medical name for the active ingredient in the medication. It is typically listed in parentheses following the brand name.

Pharmacologic Category

Palbociclib belongs to the class of drugs known as CDK4/6 inhibitors. Other medications in this category include Ribociclib (Kisqali) and Abemaciclib (Verzenio).

Dosing

Palbociclib is used to treat hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer. The recommended dosage is 125 mg taken orally once daily for 21 consecutive days, followed by 7 days off treatment. This 28-day cycle is repeated as long as the patient is benefiting from and tolerating the therapy. Always consult your healthcare provider before adjusting your dose, or if you’re seeking treatment for breast cancer, consider our telemedicine service for immediate consultation.

Dosage Forms and Strengths

Palbociclib is available as a capsule in three strengths: 75 mg, 100 mg, and 125 mg.

Administration Instructions

Palbociclib is taken orally, with food, at approximately the same time each day. The capsules should not be opened, crushed, or chewed.

Adverse Reactions and Side Effects

The most common side effects of Palbociclib include fatigue, low white blood cell count (neutropenia), infections, nausea, and anemia. These occur in more than 20% of patients. Less common side effects include vomiting, loss of appetite, diarrhea, hair thinning, and rash. Always reach out to your healthcare provider if you experience any side effects while on medication.

Contraindications

Contraindications refer to conditions or factors that serve as a reason to withhold a certain medical treatment due to the harm that it would cause the patient. Palbociclib should not be taken if you are allergic to Palbociclib or any of its ingredients. Also, it should be used with caution in patients with liver problems.

Drug to Drug Interactions

Palbociclib can interact with several other medications. These include but are not limited to CYP3A inhibitors such as Ketoconazole (Nizoral), CYP3A inducers like Rifampin (Rifadin), and certain other drugs that affect liver enzymes. Always provide a complete list of medications you’re taking to your healthcare provider to avoid potential drug interactions.

Palbociclib in Pregnancy

Palbociclib may harm an unborn baby. Therefore, it is not recommended for use during pregnancy. Women of childbearing age should use effective contraception while taking this medication and for at least three weeks after the last dose.

Palbociclib while Breastfeeding

It is not known whether Palbociclib passes into breast milk. To protect the infant, breastfeeding is not recommended while using this medication and for three weeks after the last dose.

Estimated Cost of Medication

The estimated cost of a 30-day supply of Palbociclib, using a GoodRx coupon and without insurance, is approximately $11,000. Costs can vary widely, so check with your pharmacy or insurance provider for precise figures.

Possible Alternatives

While Palbociclib is one of the primary treatments for HR-positive, HER2-negative breast cancer, alternatives do exist. Other CDK4/6 inhibitors such as Ribociclib (Kisqali) and Abemaciclib (Verzenio) may be considered. Hormonal therapies or chemotherapy may be suitable for some patients. Lifestyle changes, including a balanced diet and regular exercise, can support overall health during treatment. Discuss all alternatives with your healthcare provider before making any changes to your treatment plan. Our telemedicine service is always available for consultations.

Recent Updates on Palbociclib Research

Recent research on Palbociclib continues to demonstrate its effectiveness in treating HR-positive, HER2-negative breast cancer. Current studies are exploring its use in combination with other therapies and for different cancer types. For the most up-to-date information on this medication, consult your healthcare provider or consider utilizing our telemedicine services for immediate assistance.

Brief Legal Disclaimer: This article is for informational purposes only and not intended as medical advice. Always consult a healthcare professional for diagnosis and treatment. Reliance on the information provided here is at your own risk.